15353-j-veluchamy

4 NK cell ADCC enhances treatment efficacy in colorectal cancer | 111 References 1. Vincent MD, Kuruvilla MS, Leighl NB, Kamel-Reid S. Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS. Curr Oncol. 2012;19(Suppl 1):S33-44. 2. Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. European Journal of Cancer. 2001;37, Supplement 4(0):9-15. 3. Capdevila J, Elez E, Macarulla T, Ramos FJ, Ruiz-Echarri M, Tabernero J. Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treatment Reviews. 2009;35(4):354-63. 4. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, et al. Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti–Epidermal Growth Factor Receptor Antibody Therapies. Cancer Research. 2007;67(6):2643-8. 5. Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab– FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. New England Journal of Medicine. 2013;369(11):1023-34. 6. Bardelli A, Siena S. Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer. Journal of Clinical Oncology. 2010;28(7):1254-61. 7. Shaib W, Mahajan R, El-Rayes B. Markers of resistance to anti-EGFR therapy in colorectal cancer. J Gastrointest Oncol. 2013;4(3):308-18. 8. JeongW-J, Cha P-H, Choi K-Y. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer. World Journal of Gastroenterology : WJG. 2014;20(29):9862-71. 9. Paz-Ares LG, Gomez-Roca C, Delord J-P, Cervantes A, Markman B, Corral J, et al. Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 2011;29(28):3783-90. 10. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL. Decreased Absolute Counts of T Lymphocyte Subsets and Their Relation to Disease in Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research. 2004;10(11):3755-62. 11. Mackall CL, Fleisher TA, Brown MR, Andrich MP, Chen CC, Feuerstein IM, et al. Age, Thymopoiesis, and CD4+ T-Lymphocyte Regeneration after Intensive Chemotherapy. New England Journal of Medicine. 1995;332(3):143-9. 12. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends in Immunology.22(11):633-40. 13. Roberti M, Rocca Y, Amat M, Pampena M, Loza J, Coló F, et al. IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients. Breast Cancer Research and Treatment. 2012;136(3):659-71. 14. Seidel UJE, Schlegel P, Lang P. Natural Killer Cell Mediated Antibody-Dependent Cellular Cytotoxicity in Tumor Immunotherapy with Therapeutic Antibodies. Frontiers in Immunology. 2013;4:76.